Advertisement
Advertisement
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
23.94
USDSponsored
-0.65
-2.63%
Mar 11, 15:59 UTC -4
Closed
After-Market
23.93
-0.01
-0.04%
ARQT Earnings Reports
Positive Surprise Ratio
ARQT beat 21 of 25 last estimates.
84%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$103.29M
/-$0.05
Implied change from Q4 25 (Revenue/ EPS)
-20.24%
/-138.46%
Implied change from Q1 25 (Revenue/ EPS)
+56.86%
/-75.00%
Arcutis Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Feb 25, 2026, ARQT reported earnings of 0.13 USD per share (EPS) for Q4 25, beating the estimate of 0.11 USD, resulting in a 12.36% surprise. Revenue reached 129.50 million, compared to an expected 115.32 million, with a 12.30% difference. The market reacted with a +5.78% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.05 USD, with revenue projected to reach 103.29 million USD, implying an decrease of -138.46% EPS, and decrease of -20.24% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Legend Biotech Corporation - ADR
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.11
Actual
-$0.08
Surprise
+27.73%
BioNTech SE - ADR
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.32
Surprise
-72.12%
ADC Therapeutics SA
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.04
Surprise
+85.39%
Kamada Ltd
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.07
Actual
$0.06
Surprise
-24.15%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.43
Surprise
-112.14%
Editas Medicine, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.06
Surprise
+77.21%
Codexis, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.04
Actual
$0.11
Surprise
+357.01%
Anixa Biosciences, Inc.
Report Date
Mar 09, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.08
Surprise
+17.44%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Elutia Inc. Class A Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.14
Surprise
+1.96%
FAQ
What were Arcutis Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Arcutis Biotherapeutics, Inc. Common Stock reported EPS of $0.13, beating estimates by 12.36%, and revenue of $129.50M, 12.3% above expectations.
How did the market react to Arcutis Biotherapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 5.78%, changed from $27.01 before the earnings release to $28.57 the day after.
When is Arcutis Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Arcutis Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Arcutis Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.05 and revenue of $103.29M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement